Hoffmann-la Roche Inc.

C4 Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Juergen Wichmann

Thomas Johannes Woltering

Erwin Goetschi

Vincent Mutel

Jens-Uwe Peters

Roland Jakob-Roetne

Ravi Jagasia

Silvia Gatti McArthur

Sabine Kolczewski

Lucinda Steward

Marius Hoener

Claus Riemer

Olivier Roche

Simona Maria Ceccarelli

Rosa Maria Rodriguez Sarmiento

Eric Vieira

Wylie Solang Palmer

Geo Adam

Silvia Gatti Mcarthur

Andrew William Thomas

Rainer Eugen Martin

Luca Claudio Gobbi

Raffaello Masciadri

Cosimo Dolente

Piergiorgio Francesco Tommaso Pettazzoni

Georg Jaeschke

Synese Jolidon

Christopher G Nasveschuk

Daniel Hunziker

Yanke Liang

Lothar Lindemann

Martin Duplessis

Paul Spurr

Stephan Bachmann

Stefan Hildbrand

Pingsheng Zhang

Jason Yang

Daniela Krummenacher

Amit Srivastava

Katrina L Jackson

Mark E Fitzgerald

Joerg Huwyler

Miall Cedilote

Theresa Maria Ballard

Zhiming Dong

David Hewings

Doreen Miller

Jodie Brice

David Stephen Hewings

Daniel Bailey

Frederic Knoflach

Pingsheng Zhan

Simona M Ceccarelli

The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

Therapeutics for the degradation of mutant BRAF

The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.

Methylquinazolinone derivatives

The present invention relates to compounds of formula I wherein

Tetrazole derivatives

The invention provides novel compounds having the general formula (I) wherein R, R', R, R, Rare as defined herein, compositions including the compounds and methods of using the compounds.

Imidazole compounds as EAAT3 inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, Rare as defined herein, compositions including the compounds and methods of using the compounds.

Pyrazol compounds as EAAT3 inhibitors

The present invention relates to compounds of formula I wherein The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.

Pyrazol-pyridine derivatives

Triazole derivatives

Pyridine or pyrimidine derivatives

Imidazole derivatives

Pyridine and pyrimidine derivatives

The present invention relates to compounds of the general formula I wherein Het, R, R, W and X are as defined herein. Compounds of formula I are useful for treating neuropsychiatric disorders. 

N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders

The present invention relates to compounds of general formula I wherein R, R, Rand Rare as defined herein which may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction ('chemobrain'), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

1,7-naphthyridine derivatives

The present invention relates to compounds of general formula I wherein R, Rand Rare as defined herein which may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction ('chemobrain'), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

Pyrido[4,3-B]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders

The present invention relates to the use of compounds of general formula I wherein R', R, Rand Rare as defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, and for methods to treat a variety of neurodegenerative and neuropsychiatric diseases.

Substituted 1,6-naphthyridines

Growing community of inventors

Steinen, Germany

Juergen Wichmann